Literature DB >> 33392645

Drug-coated stent implantation vs. bypass surgery for in-stent occlusion after femoropopliteal stenting.

Yusuke Tomoi1, Yoshimitsu Soga2, Jin Okazaki3, Osamu Iida4, Tatsuya Shiraki5, Seiichi Hiramori2, Kenji Ando2.   

Abstract

The optimal revascularization for in-stent occlusion (ISO) lesions after femoropopliteal (FP) bare-nitinol stenting has not been established. We, therefore, investigated the comparison between drug-coated stent (DCS) implantation and bypass surgery (BSX) for ISO lesions after FP bare-nitinol stenting. This study was a dual-center, observational study from January 2004 to December 2015. A total of 172 ISO lesions were observed, and after excluding 120 ISO lesions, 52 ISO lesions (50 patients; mean age, 71.0 ± 9.2 years; male, 59.6%) after FP bare-nitinol stenting were enrolled. The included patients with clinical symptoms underwent either DCS implantation (n = 28) or BSX (n = 22). The primary endpoint was recurrent in-stent restenosis (ReISR); secondary endpoints were recurrent target lesion revascularization (ReTLR), recurrent occlusion (reocclusion) and major adverse limb events (MALE), and perioperative complications (POCs), respectively. ReISR or reocclusion was defined as ISR or occlusion after TLR. Stent restenosis was defined as a peak systolic velocity ratio (PSVR) > 2.4 on a duplex scan or ≥ 50% stenosis on angiography. Graft restenosis was defined as a PSV > 300 cm/s and velocity ratio 3.5 or uniformly low PSV < 45 cm/s throughout the entire graft based on graft surveillance. The mean follow-up period was 36.6 ± 25.5 months. At 2 years, the rates of freedom from ReISR, ReTLR, and MALE were not significantly different between the DCS implantation and BSX groups (68.9% vs. 73.7%, p = 0.81; 84.7% vs. 73.7%, p = 0.45; 84.7% vs. 78.6%, p = 0.60, respectively). However, the freedom from reocclusion rate was significantly lower in the DCS implantation group (81.6% vs. 100%, p = 0.04). The occurrence of POCs was not significantly different between the DCS implantation and BSX groups (7.1% vs 4.2%, p = 1.0). Although BSX was the gold-standard therapy for ISO lesions after FP bare-nitinol stenting, DCS implantation might be a good option because the rates of freedom from ReISR, ReTLR, and MALE were similar.

Entities:  

Keywords:  Bypass surgery; Drug-coated stent; Endovascular therapy; In-stent occlusion

Year:  2021        PMID: 33392645     DOI: 10.1007/s00380-020-01740-8

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  1 in total

1.  Greater coronary lipid core plaque assessed by near-infrared spectroscopy intravascular ultrasound in patients with elevated xanthine oxidoreductase: a mechanistic insight.

Authors:  Yuichi Saito; Naoto Mori; Takayo Murase; Takashi Nakamura; Seigo Akari; Kan Saito; Takaaki Matsuoka; Kazuya Tateishi; Tadayuki Kadohira; Hideki Kitahara; Yoshihide Fujimoto; Yoshio Kobayashi
Journal:  Heart Vessels       Date:  2020-11-20       Impact factor: 2.037

  1 in total
  2 in total

1.  Predictor analysis of 1-year restenosis after percutaneous transluminal angioplasty for femoropopliteal stenotic lesions using intravascular ultrasound.

Authors:  Shunsuke Kakizaki; Amane Kozuki; Yoichi Kijima; Ryoji Nagoshi; Ryudo Fujiwara; Hiroyuki Shibata; Atsushi Suzuki; Daichi Fujimoto; Syokan Kyo; Eri Masuko; Tomohiro Miyata; Junya Shite
Journal:  Heart Vessels       Date:  2021-04-08       Impact factor: 2.037

Review 2.  Diabetes and restenosis.

Authors:  Scott Wilson; Pasquale Mone; Urna Kansakar; Stanislovas S Jankauskas; Kwame Donkor; Ayobami Adebayo; Fahimeh Varzideh; Michael Eacobacci; Jessica Gambardella; Angela Lombardi; Gaetano Santulli
Journal:  Cardiovasc Diabetol       Date:  2022-02-14       Impact factor: 9.951

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.